Telesis Bio, Inc. TBIO
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 14.81M | 20.27M | 22.76M | 25.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 14.81M | 20.27M | 22.76M | 25.25M |
| Cost of Revenue | -- | 7.22M | 6.91M | 7.72M | 8.52M |
| Gross Profit | -- | 7.59M | 13.36M | 15.03M | 16.73M |
| SG&A Expenses | -- | 29.50M | 30.78M | 33.02M | 35.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 48.55M | 50.97M | 56.16M | 60.44M |
| Operating Income | -- | -33.73M | -30.70M | -33.40M | -35.19M |
| Income Before Tax | -- | -47.04M | -43.24M | -45.97M | -36.41M |
| Income Tax Expenses | -- | 20.00K | 23.00K | 24.00K | 27.00K |
| Earnings from Continuing Operations | -- | -47.06 | -43.27 | -45.99 | -36.44 |
| Earnings from Discontinued Operations | -- | -2.48M | -1.98M | -1.73M | -1.73M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -49.54M | -45.24M | -47.72M | -38.17M |
| EBIT | -- | -33.73M | -30.70M | -33.40M | -35.19M |
| EBITDA | -- | -31.52M | -28.39M | -31.21M | -33.14M |
| EPS Basic | -- | -30.82 | -28.31 | -29.54 | -23.53 |
| Normalized Basic EPS | -- | -12.73 | -8.93 | -10.05 | -10.83 |
| EPS Diluted | -- | -30.82 | -28.31 | -29.54 | -23.53 |
| Normalized Diluted EPS | -- | -12.73 | -8.93 | -10.05 | -10.83 |
| Average Basic Shares Outstanding | -- | 6.73M | 6.66M | 6.63M | 6.61M |
| Average Diluted Shares Outstanding | -- | 6.73M | 6.66M | 6.63M | 6.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |